Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

Abstract Background Non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitors show long lasting responses, but it is hard to predict which patients will profit from this treatment with the currently used marker, programmed death ligand 1 (PD-L1). We hypothesized that circulating...

Full description

Bibliographic Details
Main Authors: Menno Tamminga, Sanne de Wit, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Leon W. M. M. Terstappen, Harry J. M. Groen
Format: Article
Language:English
Published: BMJ Publishing Group 2019-07-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Circulating tumor cells (CTC)
Non-small cell lung cancer (NSCLC)
Immunotherapy
Checkpoint inhibitors
Tumor derived extracellular vesicles (tdEV)
Durable response
Online Access:http://link.springer.com/article/10.1186/s40425-019-0649-2

Internet

http://link.springer.com/article/10.1186/s40425-019-0649-2

Similar Items